scholarly journals Clinical Effect of Lung Qi-Diffusing and Tumor-Clearing Decoction in the Treatment of Advanced Lung Cancer

2021 ◽  
Vol 5 (6) ◽  
pp. 38-42
Author(s):  
Limei Qin
Keyword(s):  
Lung Cancer ◽  
Adverse Reactions ◽  
Clinical Effect ◽  
Reference Group ◽  
Advanced Lung Cancer ◽  
Control Group ◽  
Therapeutic Effects ◽  
Study Group ◽  
Conventional Chemotherapy

Objective: The main purpose of this study is to explore the efficacy of lung qi-diffusing and tumor-clearing decoction in the treatment of advanced lung cancer. Methods: Eight patients with advanced lung cancer in Inner Mongolia Baicaotang Qin’s Zhong Meng Medical Hospital from February 2017 to October 2020 were randomly selected and divided into two groups, a control group and a study group, by the digital table method. The control group was treated with conventional chemotherapy, while the study group was treated with lung qi-diffusing and tumor-clearing decoction on this basis. The therapeutic effects of the two groups were observed. Results: The improvement in symptoms of the patients in the study group was higher than that of the reference group, and the incidence of adverse reactions was lower among patients in the study group compared to the reference group, P < 0.05. The serum immunological indexes, CD3+, CD4+, and CD4+/CD8+, of study group were higher than those of the reference group, and the quality-of-life score of the study group was higher than that of the reference group, P < 0.05. Conclusion: The clinical effect of lung qi-diffusing and tumor-clearing decoction in the treatment of patients with advanced lung cancer is significant. It effectively improves the immune indicators and reduces adverse reactions.

scholarly journals The Value of Shashen Maidong Decoction in the Treatment of Advanced Lung Cancer

2021 ◽  
Vol 5 (5) ◽  
pp. 52-56
Author(s):  
Limei Qin
Keyword(s):  
Lung Cancer ◽  
Inner Mongolia ◽  
Adverse Reactions ◽  
Clinical Effect ◽  
Reference Group ◽  
Remission Rate ◽  
Advanced Lung Cancer ◽  
Study Group ◽  
Conventional Chemotherapy

Objective: This study mainly explores the clinical effect of Shashen Maidong Decoction in the treatment of advanced lung cancer. Methods: Twelve patients with advanced lung cancer from Inner Mongolia Baicaotang Qin’s Zhong Meng Medical Hospital were randomly selected from February 2016 to February 2021. They were divided into two groups: the reference group and study group by the digital table method. The reference group was treated with conventional chemotherapy while the study group was treated with Shashen Maidong Decoction plus conventional chemotherapy. Results: The remission rate of the study group was higher than that of the reference group, and the incidence of adverse reactions was lower than that of the reference group, P < 0.05. The levels of CD3+, CD4+, and CD4+/CD8+ in the study group were higher than those in the reference group (P < 0.05). After treatment, the quality of life score of the study group was higher than that of the reference group (P < 0.05). Conclusion: Shashen Maidong Decoction can effectively reduce adverse reactions and improve the condition of patients in the treatment of advanced lung cancer.

scholarly journals Clinical Effect of Auricular Point Sticking in Patients with Lung Cancer Receiving Chemotherapy

2021 ◽  
Vol 5 (6) ◽  
pp. 73-77
Author(s):  
Xiaorui Zhu
Keyword(s):  
Lung Cancer ◽  
Stress Response ◽  
Adverse Reactions ◽  
Clinical Effect ◽  
Clinical Symptoms ◽  
Auricular Point Sticking ◽  
Jiangxi Province ◽  
Control Group ◽  
Study Group ◽  
Auricular Point

Objective: To discuss and analyze the clinical effect of auricular point sticking in lung cancer chemotherapy. Methods: Sixty-two patients with lung cancer treated with chemotherapy in Suqian Traditional Chinese Medicine Hospital of Jiangxi Province were selected for case evaluation and analysis. The time span of the research was from June 2020 to June 2021. The patients were divided into two groups: a study group (n = 31) and a control group (n = 31) based on their medical record numbers. All the patients were treated with conventional western medicine before and after chemotherapy to prevent adverse reactions; however, the patients in the study group were also treated with auricular point sticking in addition to the former. The relevant indexes of the two groups were compared. Results: The incidence of adverse reactions was significantly lower in the study group compared to the control group (P < 0.05); the rate of symptomatic relief of the patients in the study group was higher than that of the control group (P < 0.05); the stress response indexes toward chemotherapy of the study group were better than those of the control group (P < 0.05). Conclusion: Auricular point sticking for patients with lung cancer who are receiving chemotherapy can reduce the incidence of adverse reactions, alleviate clinical symptoms, such as chest distress, asthma, and poor appetite, significantly alleviate stress response caused by chemotherapy, as well as promote the treatment effect; thus, it is worthy of promotion.

scholarly journals Application Value of Lung-Fire-Clearing, Phlegm-Resolving, and Bowels-Relaxing Decoction in Treating Lung Cancer of Phlegm-Heat Pattern

2021 ◽  
Vol 5 (4) ◽  
pp. 103-107
Author(s):  
Limei Qin
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Reference Group ◽  
Control Group ◽  
Cytokeratin 19 ◽  
Study Group ◽  
Clinical Effects ◽  
Carbohydrate Antigen 125 ◽  
Heat Pattern

Objective: This article explores the clinical effects of lung-fire-clearing, phlegm-resolving and bowels-relaxing decoction in the treatment of lung cancer of phlegm-heat pattern. Methods: A total of 6 cases of lung cancer patients with phlegm-heat pattern were randomly selected from Inner Mongolia Baicaotang Qin’s Zhong Meng Medical Hospital from March 2018 to December 2020 to conduct the study. They were divided into the reference group and the study group by using the digital table method. The patients in the reference group were treated with conventional Western medicine whereas the patients in the study group were treated with lung-fire-clearing, phlegm-resolving, and bowels-relaxing decoction to observe the curative effect. Results: There were no significant differences in the levels of the tumor markers between the two groups before treatment (P > 0.05). However, after treatment, the levels of cytokeratin 19 soluble fragments (CYFRA21-1), carbohydrate antigen 125 (CA125), and carcinoembryonic antigen (CEA) in the study group were lower than those in the control group (P < 0.05). The effective rate and the quality of life score of the study group were higher than those of the reference group while the incidence of adverse reactions was lower than that of the reference group, P < 0.05. Conclusion: Lung-fire-clearing, phlegm-resolving, and bowels-relaxing decoction can effectively improve the symptoms of patients with lung cancer and improve their quality of life.

scholarly journals Effects of Docetaxel Combined with Icotinib on Serum Tumor Markers and Quality of Life of Patients with Advanced Non-Small Cell Lung Cancer

2020 ◽  
Author(s):  
Huawei LIN ◽  
Jing CHANG ◽  
Jun LI
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Tumor Markers ◽  
Adverse Reactions ◽  
Advanced Nsclc ◽  
Small Cell ◽  
Control Group ◽  
Study Group ◽  
Small Cell Lung

Background: To investigate the effects of docetaxel combined with icotinib on tumor markers in serum and quality of life of patients with advanced non-small cell lung cancer (NSCLC). Methods: Overall, 121 patients with advanced NSCLC, admitted to the Third Affiliated Hospital of Shandong First Medical University, China from 2017- 2018 were selected as subjects. Among them, 58 patients treated with docetaxel combined with icotinib for chemotherapy were considered as study group, and 63 patients treated with paclitaxel combined with carboplatin as control group. The clinical efficacy, adverse reactions, and ECOG scores of the two groups were observed. CEA, CA125, and SCC (Tumor markers) levels of the two groups before and after treatment were detected by chemiluminescence immunoassay (CLIA). Results: The leukopenia, oral mucosa ulcer and mild numbness in the control group were significantly higher than those in the study group (P<0.05). After treatment, ECOG scores of both groups decreased (P<0.05), and the ECOG score of the study group was significantly higher than that of the control group (P<0.05). The serum CEA, CA125 and SCC levels of the study group and the control group after treatment decreased significantly compared with that before treatment (P<0.05). Conclusion: Application of docetaxel combined with icotinib for chemotherapy of patients with advanced NSCLC can effectively reduce the serum levels of CEA, SCC, and the CA125. Docetaxel combined with icotinib can significantly reduce adverse reactions and better improve the quality of life of patients compared with paclitaxel combined with carboplatin, which is worthy of clinical promotion.  

scholarly journals Docetaxel HIPEC Combined with Endostar versus Docetaxel HIPEC Alone in Treatment of Malignant Ascites：A Retrospective Study

2021 ◽  
Author(s):  
Jing Wu ◽  
Hao Jiang ◽  
Liting Chen ◽  
Bingqi Yu ◽  
Zhibing Wu
Keyword(s):  
Qualitative Data ◽  
Adverse Reactions ◽  
Clinical Effect ◽  
Objective Response ◽  
Malignant Ascites ◽  
Control Group ◽  
Observation Group ◽  
Improvement Rate ◽  
Significant Difference

Abstract Objective：The purpose of this study is to retrospectively observe the clinical efficacy and adverse reactions of docetaxel hyperthermic intraperitoneal chemotherapy (HIPEC) combined with endostar in treatment of malignant ascites. Methods：56 cases of malignant ascites admitted to Zhejiang Hospital from July 2019 and October 2020 had received no less than second-line chemotherapy. The observation group (n = 29) was treated with endostar 60mg d1,4,7 Q3W intraperitoneal injection combined with docetaxel 60mg/m2 d4 HIPEC Q3W for 2 cycles. The control group (n = 27) was just treated with docetaxel 60mg/m2 d1 HIPEC Q3W for 2 cycles. The general clinical data and qualitative data of the treatment results were processed by SPSS26.0 using χ2 test, and quantitative data were processed by t test. When P < 0.05, statistical data can be considered statistically significant.Results：There were significant differences between the observation group and the control group in objective response rate (ORR) (65.5% vs 37.0%，P=0.033)，in the improvement rate of KPS (48.3% vs 22.2%, P=0.042)，also in the median control time (57dvs 45d，P=0.027). The incidence of III to IV adverse reactions was low, and no treatment-related death was observed. There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion：Endostar combined with docetaxel HIPEC has good clinical effect on malignant ascites and can improve patients’ quality of life, and the adverse reactions can be tolerated.

scholarly journals Evaluation of quality of life in patients with locally advanced non-small cell lung cancer treated with combined radiochemotherapy

2003 ◽  
Vol 11 (3) ◽  
pp. 196-196
Author(s):  
Suzana Isakovic-Vidovic ◽  
Nenad Borojevic ◽  
Ljiljana Radosevic-Jelic ◽  
Tatjana Pekmezovic
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Locally Advanced ◽  
Small Cell ◽  
Control Group ◽  
Study Group ◽  
Small Cell Lung ◽  
Combined Radiochemotherapy

Background: The aim was to investigate the application of radiopotentiation which was initiated by the fact that in patients with locally advanced non-small cell lung cancer there is a high risk of relapse due to failure in local control of the disease and the risk of systemic micrometastases. The other aim was the evaluation of quality of life. Methods: A study group consisted of 67 patients. Patients were first treated with TD30 Gy in 10 fractions during 2 weeks (5 fractions per week) with a potentiation by 20 mg/m 2 of carboplatinol intravenous bolus infusion just prior to each radiotherapy fraction. After a 2-week pause, additional radiation of 25 Gy in 10 fractions was applied during 2 weeks (5 fractions/week) with a potentiation by 20 mg/m 2 of carboplatinol. Total tumor dose (TTD) was 55 Gy (30+25 Gy) in 20 fractions, total duration of the therapy was 6 weeks, and total dose of carboplatinol was 600 mg. A control group consisted of 70 patients and they were treated with a radical radiotherapy with a conventional fractionation (60 Gy in 30 fractions, 2 Gy per day, 5 fractions per week). Quality of life was evaluated by Karnofsky performance scale (KI), at the beginning of the treatment, after the completion of the whole course of treatment, and during follow-up at regular check-ups. Results After the completion of the whole course of treatment most of patients had KI 80%. Analysis made during the last check-up showed statistically significant low KI. In both study and control groups KI was significantly higher at the beginning of the treatment than KI after the completion of the whole course of treatment (p=0.001). However, the analysis of KI at the time of the completion of the whole course of treatment showed significantly better KI in study group (p=0.036) than in control group. Conclusion: These results showed that the combined radiochemotherapy treatment is well tolerated.

scholarly journals Clinical Study on Treatment of Patients with Acute Cerebral Infarction by Huayu Tongluo Decoction Combined with Edaravone Injection

2020 ◽  
Vol 185 ◽  
pp. 03011
Author(s):  
Wentao Zhang ◽  
Ping Zuo ◽  
Feng Wang ◽  
Zhihua Liu ◽  
Yinglin Cui
Keyword(s):  
Quality Of Life ◽  
Cerebral Infarction ◽  
Clinical Effect ◽  
Clinical Symptoms ◽  
Effective Rate ◽  
Acute Cerebral Infarction ◽  
Control Group ◽  
Study Group ◽  
Nihss Score

To study the clinical effect of Huayu Tongluo Decoction combined with edaravone injection in the treatment of patients with acute cerebral infarction.86 patients with acute cerebral infarction received from our hospital from October 2016 to May 2018 were randomly divided into study group (n=43) and control group (n=43). Routine treatment was performed in both groups. On the basis of this, the control group was treated with edaravone injection, and the research group was treated with Huayu Tongluo Decoction combined with edaravone injection. The effects of treatment, the degree of neurological deficit (NIHSS score), TCM syndrome scores and quality of life (QLI score) before and after treatment were compared. The total effective rate of the study group [95.35% (41/43)] was higher than that of the control group [79.07% (34/43)] (P<0.05). After treatment, the main symptoms, secondary diseases and tongue and pulse of the two groups were treated. The scores were lower than before treatment, and the study group was lower than the control group (P<0.05). After treatment, the NIHSS and QLI scores of the two groups were better than before treatment, and the NIHSS score of the study group was lower than that of the control group, and the QLI score was higher than the control. Group (P<0.05). The clinical effect of Huayu Tongluo Decoction combined with edaravone injection in the treatment of patients with acute cerebral infarction is significant, which can further improve the clinical symptoms, improve neurological function and improve the quality of life.

Efficacy of a Propolis-Based Syrup (FARINGEL) in Preventing Radiation-Induced Esophagitis in Locally Advanced Lung Cancer

Chemotherapy ◽  
2018 ◽  
Vol 63 (2) ◽  
pp. 76-82
Author(s):  
Edy Ippolito ◽  
Barnaba Floreno ◽  
Carla Germana Rinaldi ◽  
Lucio Trodella ◽  
Federica Loretta Meroni ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Statistical Significance ◽  
Locally Advanced ◽  
Advanced Lung Cancer ◽  
Control Group ◽  
Study Group ◽  
Lung Cancer Patients ◽  
Radiation Induced ◽  
Locally Advanced Lung Cancer ◽  
Involved Field

Aim: To evaluate the efficacy of a propolis-based syrup, FARINGEL®, in preventing radiation-induced esophagitis in locally advanced lung cancer patients. Methods. Patients were treated with concurrent chemoradiotherapy (CRT) using involved-field radiotherapy (RT). Every patient received FARINGEL at the beginning of CRT until the first follow-up. The data of the study group were compared with the data of a control group treated without the administration of the syrup. Results: Forty-five patients were enrolled. Forty-one (91.1%) completed the protocol and were evaluable for esophagitis. Grade ≥2 toxicity occurred in 9/41 patients (22%). No differences in overall toxicity were detected between the study group and the control group (n = 55, 60.9 vs. 54.5%; p = ns). Grade 2–3 esophagitis was lower in the study group in comparison with the control group (22 and 38%, respectively), but statistical significance was not reached (p = 0.09). However, the onset of grade ≥2 esophagitis was delayed in the study group compared to the control group, occurring at higher doses of RT (41.8 vs. 25.4 Gy; p < 0.001). Furthermore, the mean number of interruption days for esophagitis was lower in the study group than in the control group (0.6 ± 2.0 vs. 2.1 ± 3.6; p = 0.025). Conclusion: FARINGEL was well-tolerated and delayed esophagitis that was induced by CRT for locally advanced lung cancer.

scholarly journals Artificial Intelligence-Based Computed Tomography Imaging Characteristics for the Diagnosis Effect of High Flow Nasal Cannula in the Treatment of Patients with Advanced Lung Cancer and Chronic Obstructive Pulmonary Disease

2021 ◽  
Vol 2021 ◽  
pp. 1-10
Author(s):  
Xiaobin Tang ◽  
Jiang Yuan
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Clinical Symptoms ◽  
Effective Rate ◽  
Advanced Lung Cancer ◽  
Control Group ◽  
Chronic Obstructive ◽  
Observation Group ◽  
Obstructive Pulmonary Disease

Objective. This study was to compare the effects of symptomatic treatment and high flow nasal cannula (HFNC) treatment on patients with advanced lung cancer complicated with chronic obstructive pulmonary disease (COPD) and to explore the clinical application effect of HFNC treatment in such patients. Methods. 80 patients with advanced lung cancer and COPD admitted to the hospital were selected as the research objects. They were randomly divided into a control group (n = 40) and an observation group (n = 40). The computed tomography (CT) image data of all patients were classified. The neural network was trained to obtain the network weights. Based on surgery, radiotherapy, and chemotherapy, patients in the control group received anti-inflammatory, phlegm, and other symptomatic treatments, while patients in the observation group received HFNC treatment on this basis. The blood gas analysis results, clinical symptoms (cough, wheezing, rales, etc.), inflammatory factors (high-sensitivity C-reactive protein (hs-CRP), plateletcrit (PCT), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6)), and quality of life of the two groups were compared and analyzed. Results. When the model MSE was the smallest, the corresponding hidden layer neuron node value was 49, so 49 was set as the optimal number of hidden layer neuron nodes. CT images were imported into the constructed model system, and the model diagnosis system could still diagnose and classify under the premise that the pathological characteristics were not obvious. There was no significant difference in clinical data between the two groups of patients before treatment ( P > 0.05 ). After treatment, the clinical symptoms, arterial partial pressure of carbon dioxide (PaCO2), arterial partial pressure of oxygen (PaO2), hs-CRP, PCT, TNF-α, and IL-6 levels were greatly reduced; those of patients in the observation group were much better in contrast to those of the control group ( P < 0.05 ). The total effective rate in the observation group was 97.5%, and the effective rate in the control group was 87.5%. After treatment, the functional assessment of cancer therapy-lung (FACT-L) score was obviously higher than that before treatment ( P < 0.05 ). After treatment, the quality of life in the observation group was increased by 45.69% compared with that before treatment, and the quality of life in the control group was increased by 35.77%. Conclusion. HFNC therapy can improve the lung function of patients with advanced lung cancer and COPD, alleviate the development of the disease, and improve the quality of life of patients.

scholarly journals Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

2021 ◽  
Vol 37 (4) ◽  
Author(s):  
Yu-jie Cui ◽  
Jia Liu ◽  
Miao-miao Liu ◽  
Hong-zhen Zhang
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Effect ◽  
Small Cell ◽  
Control Group ◽  
Small Cell Lung ◽  
Experimental Group

Objectives: To evaluate the clinical effect of apatinib combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Eighty patients with advanced NSCLC treated in Hebei General Hospital from January 2017 to July 2020 were randomly divided into two groups: the experimental group and the control group, each with 40 cases. Patients in the control group were treated with conventional paclitaxel combined with cisplatin chemotherapy, while patients in the experimental group were treated with apatinib mesylate tablets based on the treatment of the control group. After treatment, tumor efficacy evaluation was conducted on all patients every two cycles, and the therapeutic effect, adverse drug reactions, improvement of quality-of-life scores prior to and after treatment, and changes of indicators such as tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 153(CA153) were compared and analyzed between the two groups.  Results: The total effective rate of the experimental group was 67.5%, which was significantly better than the 45% of the control group (p=0.04); The incidence of adverse drug reactions in the experimental group was 25%, while that in the control group was 37.5%, with no significant difference (p=0.23); Moreover, the improvement rate of quality of life scores in the experimental group was significantly higher than that in the control group (p=0.03), and the levels of CEA and CA153 in the experimental group were significantly lower after treatment than those in the control group, with a statistically significant difference (p=0.01). Conclusion: Apatinib combined with conventional chemotherapy is effective in the treatment of advanced non-small cell lung cancer, the quality of life can be significantly improved, tumor markers can be significantly reduced, and adverse reactions will not be significantly increased. doi: https://doi.org/10.12669/pjms.37.4.4066 How to cite this:Cui Y, Liu J, Liu M, Zhang H. Observation on the Clinical Effect of Apatinib Combined with Chemotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer. Pak J Med Sci. 2021;37(4):---------.   doi: https://doi.org/10.12669/pjms.37.4.4066 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sign in / Sign up

Export Citation Format

Share Document